The Lupus biomarker panel has been developed using Sense Proteomic’s proprietary protein array technology that permits rapid identification of autoantibody biomarkers for cancer and autoimmune diseases, the company said.
Rachel Fallon, joint CEO, said: “We expect this biomarker panel to make a real difference in disease outcome for patients. In addition to facilitating the development of new drug treatments for Lupus, it should greatly improve the early diagnosis of the disease and lead to better control and management of systemic lupus erythematosus (SLE) through improved patient monitoring both within clinical practice and within clinical trials.”